As a result of the significant disruption that is being caused by the COVID-19 pandemic we are very aware that many researchers will have difficulty in meeting the timelines associated with our peer review process during normal times. Please do let us know if you need additional time. Our systems will continue to remind you of the original timelines but we intend to be highly flexible at this time.
Aims and scope
EJNMMI Research publishes new basic, translational and clinical research in the field of nuclear medicine and molecular imaging. Regular features include original research articles, rapid communication of preliminary data on innovative research, interesting case reports, editorials, and letters to the editor. Educational articles on basic sciences, fundamental aspects and controversy related to pre-clinical and clinical research or ethical aspects of research are also welcome. Timely reviews provide updates on current applications, issues in imaging research and translational aspects of nuclear medicine and molecular imaging technologies.
The main emphasis is placed on the development of targeted imaging with radiopharmaceuticals within the broader context of molecular probes to enhance understanding and characterisation of the complex biological processes underlying disease and to develop, test and guide new treatment modalities, including radionuclide therapy.
Announcement of Editor-in-Chief change
As of April 1st, 2021 EJNMMI Research has a new Editor-in-Chief. Please welcome Wim J. G. Oyen.
Thank you very much to Angelika Bischof Delaloye for establishing EJNMMI Research as Editor-in-Chief since the launch of the journal in 2011.
COVID-19 and impact on peer review
Articles
-
-
Comparison of FDG and FMISO uptakes and distributions in head and neck squamous cell cancer tumors
-
Angiogenesis imaging study using interim [18F] RGD-K5 PET/CT in patients with lymphoma undergoing chemotherapy: preliminary evidence
-
The pharmacokinetics of [18F]UCB-H revisited in the healthy non-human primate brain
-
Region- and voxel-based quantification in human brain of [18F]LSN3316612, a radioligand for O-GlcNAcase
-
Anaesthesia and physiological monitoring during in vivo imaging of laboratory rodents: considerations on experimental outcomes and animal welfare
-
Gastrointestinal transit measurements in mice with 99mTc-DTPA-labeled activated charcoal using NanoSPECT-CT
-
Comparative gallium-68 labeling of TRAP-, NOTA-, and DOTA-peptides: practical consequences for the future of gallium-68-PET
-
About inflammation and infection
-
Quantitative capabilities of four state-of-the-art SPECT-CT cameras
EJNMMI Journal Family
Discover featured content, editor’s highlights, and the latest research via our Gateway to the EJNMMI Journal Family.
Annual Journal Metrics
-
Speed
40 days to first decision for reviewed manuscripts only
34 days to first decision for all manuscripts
92 days from submission to acceptance
22 days from acceptance to publicationCitation Impact
2.640 - 2-year Impact Factor
2.514 - 5-year Impact Factor
1.005 - Source Normalized Impact per Paper (SNIP)
0.945 - SCImago Journal Rank (SJR)Usage
303,200 Downloads
263 Altmetric Mentions
Need help with APC funding?
We offer a free open access support service to make it easier for you to discover and apply for article-processing charge (APC) funding. Learn more here.
Check if your institution is a member
More than 500 institutions have partnered with BMC through the membership program. As an affiliated Author from a member institution, you may be entitled to submit your manuscript without paying the article processing charge (APC) or with a discount. Check here if your institution is a member!
Browse the journal's topical collections
The journal now offers Thematic Series related to a special topic. Browse the available list of collections or find out about the latest articles published for example in "Novel Theragnostic Drugs" or "PSMA Targeted Imaging and Therapy: Prostate and Other Cancers".
Nuclear medicine is a vibrant and rapidly developing field in biomedical research. Within the family of EJNMMI journals, EJNMMIresearch focuses on translational research, aiming to be the bridge between basic and and clinical research in nuclear medicine, molecular imaging as well radioligand-based therapy and related concepts of targeted therapies. EJNMMIresearch positions itself at the cross-roads of innovative research in biology, genetics, immunology, medicine, radiochemistry, radiopharmacy, radiophysics, dosimetry and instrumentation.
EJNMMIresearch encourages submission of original, cutting-edge basic, translational and early clinical research. This includes rapid communication of proof-of-concept or even preliminary findings. EJNMMIresearch also welcomes submission of state-of-the-art educational papers, reviews and short communications. Editorials and Letters-to-the-Editor are an integral and indispensable part of lively interaction within the scientific community to exchange thoughts and opinions. Occasionally, case reports will also be considered. EJNMMIresearch’s fully Open Access model of publication facilitates rapid processing after rigorous peer review of the submitted manuscripts.
As an established member of the five Journals in the EJNMMI family of Journals (www.springeropen.com/p/nuclear-medicine), EJNMMIresearch also encourages high-quality submissions, which are within the scope of EJNMMIresearch, but cannot be acccomodated by the other Journals in the family. Conversely, original manuscripts not accepted by EJNMMIresearch may prove to be a better fit with other Journals in the family.
On behalf of the entire EJNMMIresearch team, thank you for considering EJNMMIresearch as the journal to publish your research.
Wim J.G. Oyen, Editor-in-Chief
Humanitas University Milan, Italy and Rijnstate Arnhem, The Netherlands
Follow
- ISSN: 2191-219X (electronic)